

REFERENCES

1. Jabbour E, Estey E, Kantarjian H. Adult Acute Myeloid Leukemia. *Mayo Clin Proc* 2006; 81: 247-60.
2. Lowenberg B, Downing J, Burnett A. Acute Myeloid Leukemia. *N Engl J Med* 1999; 341: 1051-61.
3. Redaelli A, Lee J, Stephens J, Pashos C. Acute Myeloid Leukemia: Epidemiology and clinical burden. *Expert Rev Anticancer Ther* 2003 ; 3:695-710.
4. Sandler D, Poss J. Epidemiology of Acute Leukemia in Children and Adults. *Semin Oncol* 1997; 24: 3-16.
5. Greenlee R, Hill-Harmon M, Murray T, Thun M. Cancer Statistics 2001. *Ca Cancer J Clin* 2001; 51: 15-36.
6. Ries Lag, Eisner M, Kosary C, Hankey B, Miller B, Miller B, et al. SEER Cancer Statistics Review. National Cancer Institute 2004; 1975-2004.
7. Elattar I. Cancer Registry of National Cancer Institute of Egypt. 2002-2003, 2003.
8. Ilhan G, Karakus S, Andic N. Risk factors and primary prevention of acute leukemia. *Asian Pac J Cancer Prev* 2006;7:515-7.
9. Reynolder P, Von Behren J, Elkin EP. Birth Characteristics and Leukemia in Young Children. *AM J Epidemiol* 2002; 155: 546-53.
10. Pogoda J, Preston-Martin S, Nichols P, Ross R. Smoking and risk of acute myeloid leukemia: Results from a Los Angeles County Case-Control Study. *Am j Epidemiol* 2002;55: 546-53.
11. Aquino V. Acute Myelogenous Leukemia. *Curr Probl Pediatr Adolesc Health Care* 2002; 32: 50-8.
12. Gurney J, Severson R, Davis S. Incidence of cancer in children in The USA Sex, Race, and 1- year Age-Specific Rates by histological type. *Cancer* 1995; 75: 2186 - 95.
13. Chen C, Yang C, Yang M, Lee K, Kwang W, You JY, et al. Pretreatment Prognostic Factors and Treatment Outcome in Elderly Patients with DE Novo acute Myeloid leukemia. *Annals of Oncology* 2005; 16: 1366-73.
14. Pui C. Childhood Leukemias. *N Engl J Med* 1995; 332: 1618-30.
15. Bhatia S, Neglia J. Epidemiology of Childhood acute myelogenous leukemia. *J pediatr Hematol Oncol* 1995; 17: 94-100.

16. Ptzsch c, Voigtlander T, Lübbert M. p53 Germline Mutation in a Patient with Li-Fraumeni Syndrome and Three metachronous malignancies. *J Cancer Res Clin oncol* 2002; 128:456-60.
17. Moorman A, Roman E, Willett E, Dovey G, Cartwright R, Mergan G. Karyotype and Age in acute myeloid leukemia. Are they linked? *Cancer Genet Cytogenet* 2001; 126: 155-61.
18. Bloomfield C, Lawrence C, byrd J. frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. *Cancer res* 1998; 58: 4173-9.
19. Sanderson R, Johnson P, Maguire C, Moorman A, Roman E, Willett E, et al. Population-Based Study of unselected acute myeloid leukemia cases reveals distinct cytogenetic pathways analogous to therapy-related AML/MDS. *Blood* 2003; 102.
20. Head D. Revised Classification of acute myeloid leukemia. *Leukemia* 1996; 10: 1826 -31.
21. Rossi G, pelizzari A, bellotti D, tonelli M, barlati S. Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. *Leukemia* 2000; 14: 636-41.
22. Preston D, kusumi S, tomonage M. Cancer incidence in atomic bomb survivors. Part III Leukemia, lymphoma and multiple myeloma, 1950-1987. *Radiat res* 1994; 137: 68-97.
23. Kossman S, Weiss M. Acute Myelogenous Leukemia after exposure to stritium-89 for the treatment of adenocarcinoma of the prostate. *Cancer* 2000; 88: 620-4.
24. Pui C, Ribeiro R, Hancock M. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia *N Engi J Med* 1991; 325: 1682-7.
25. Savitz D, Andrews K. Review of epidemiology evidence on benzene and lymphatic and hematopoietic cancers. *Am J Int Med* 1997; 31: 287.
26. Flodin U, Anderson L, Anjou C. A Case-Referral Study on acute myeloid leukemia, background radiation and exposure to solvents and other agents. *Scand J Work Environ Health* 1981; 7: 169.
27. Ben-David Y, Bernstein A. Friend Virus-Induced Erythroleukemia and the multistage nature of cancer. *Cell* 1991; 66: 831.
28. Kerr J, Barah F, Cunniffe V, Smith J, Valley P, Will Am, et al. Association of Acute Parvovirus B19 infection with new onset of acute lymphoblastic leukemia. *J Clin Pathol* 2003; 56: 873-5.
29. Cheson B, Bennett J, Kopecky K, Büchner T, Willman C, Estey Eh, et al. Revised recommendation of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol* 2003; 21: 4642-9.

30. Neugut A, Robinson E, Nieves J, Murray T, Tsai W. Poor survival of treatment-related acute nonlymphocytic leukemia. *Jama* 1990; 264: 1006.
31. Norval E, Raubenheimer E. Second malignancies in Hodgkin's disease: A review of the literature and report of a case with a secondary Lennert's lymphoma. *J Oral Maxillofac Pathol* 2014; 18:S90-5.
32. Nottage K, Lanctot J, Li Z, Neglia J, Bhatia S, Hammond S, et al. Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study. *Blood* 2011; 117(23):6315-8.
33. Van leeuwen F. Risk of acute myelogenous leukemia and myelodysplasia following cancer treatment. *Baillieres Clin Hematol* 1996; 9; 57-85.
34. Gojo I, Karp J. The impact of biology on the treatment of secondary AML. *Cancer Treat Res* 2001; 108: 231-55.
35. Pedersen-Bjergaard J, Philip P, Larsen S. Therapy-related myelodysplasia and acute myeloid leukemia: Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. *Leukemia* 1993; 1975-86.
36. Grimwade D, Walker H, Oliver F. The importance of diagnostic cytogenetics on outcome of AML: Analysis of 1612 patients entered into MCR AML 10 trial. *Blood* 1998; 92:2322-33.
37. Warner J, Wang J, Hope K, Dice J. Concepts of human leukemic development. *Oncogene* 2004;23; 7146-77.
38. Jordan C, Guzman M. Mechanisms controlling pathogenesis and survival of leukemic stem cells. *Oncogene* 2004; 23:7178-87.
39. Tallman M, Gilliland G, Rowe J. Drug therapy for myeloid leukemia. *Blood* 2005; 106: 1154-63.
40. Rowe J, Tallman M. intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged? *Blood* 1997; 90: 2121-6.
41. Mazzotta P, Kwasnicka A, Kutas G. Cancer Chemotherapy: The Role of Pharmacological Agents in the Management of Hematological Malignancies. *News and Views* 2001; 79: 28-44.
42. Wang W, Tzeng C, Chiou T. High-Dose Cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. *Jpn J Clin Oncol* 1997; 27: 54-157.
43. Ogbomo H, Michaelis M, Klassert D, Doer H, Cinatl J. Resistance to cytarabine induces the up-regulation of NKG2D ligands and enhances natural killer cell lysis of leukemic cell. *Neoplasia* 2008; 10: 1402-10.
44. Perry, Michael j. *The chemotherapy source book*. Philadelphia: wolters kluwer health/Lippincott William&wilkins 2008: 80.

45. Pigneux A, Perreau V, Jourdan E. Adding Lomustine To Idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results. *Haematologica* 2007; 92: 1327-34.
46. Bachur N, Huffman D. Daunorubicin Metabolism: Estimation of daunorubicin reductase. *Br J Pharmacy* 1971; 43: 828-33.
47. Mortensen M: Inadvertent Intrathecal Injection of daunorubicin with fatal outcome. *Med Pediatr Oncol* 1992; 20: 249-53.
48. Greenlee R, Hill-Harmon M, Taylor M, Thun M. Cancer statistics 2001. *CA Cancer J Clin* 2001; 51:15–36.
49. Cortes J, Kantarjian HM. Acute lymphoblastic leukemia: a comprehensive review with emphasis on biology and therapy. *Cancer*. 1995; 76:2393–417.
50. Ries L, Smith M, Gurney J. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda: National Cancer Institute 1999; 1975 - 1995.
51. Groves F, Linet M, Devesa S. Epidemiology of leukemia: overview of patterns of occurrence. In: Henderson ES, Lister TA, Greaves MF, editors. *Leukemia*, 6th edition. Philadelphia: WB Saunders 1996:145–59.
52. Sandler D. Epidemiology and etiology of leukemia. *Curr Opin Oncol* 1990;2:3–9.
53. Pombo de Oliveira M, Awad F, Foroni L. Lymphoblastic leukaemia in Siamese twins: evidence for identity. *Lancet*. 1986; 2:969 –70.
54. Faderl S, Jeha S, Kantarjian H. The biology and therapy of adult acute lymphoblastic leukemia. *Cancer* 2003; 98: 1337- 54.
55. Li FP. Epidemiology of cancer in childhood. In: Nathan DG, Oski FA, editors. *Hematology of infancy and childhood*, 4th edition. Philadelphia: WB Saunders 1993:1102.
56. Chessells J, Harrison G, Richards S. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. *Arch Dis Child* 2001; 85: 321–5.
57. Taub J. Relationship of chromosome 21 and acute leukemia in children with Down syndrome. *J Pediatr Hematol Oncol* 2001; 23:175–8.
58. Mertens A, Wen W, Davies S. Congenital abnormalities in children with acute leukemia: a report from the Children's Cancer Group. *J Pediatr* 1998; 133:617–23.
59. Janik-Moszant A, Bubala H, Stojewska M, Sonta-Jakimczyk D. Acute lymphoblastic leukemia in children with Fanconi anemia. *Wiad Lek* 1998; 51:285–8.

60. Ichimura M, Ishimura T, Belsky JL. Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950-1971: radiation dose, years after exposure, age at exposure, and type of leukemia. *J Radiat Res (Tokyo)* 1978; 19:262–82.
61. Mukhin VN. Acute leukemia in adults: morbidity in Donetsk region of Ukraine before and after Chernobyl's accident. *Ter Arkh* 2000; 72:60–2.
62. Brown WM, Doll R. Mortality from cancer and other causes after radiotherapy for ankylosing spondylitis. *Br Med J* 1965; 5474:1327–32.
63. Stewart A, Kneale G. Radiation dose effects in relation to obstetric x-rays and childhood cancer. *Lancet* 1970; 1:1185–8.
64. Shore D, Sandler D, Davey F. Acute leukemia and residential proximity to potential sources of environmental pollutants. *Arch Environ Health*. 1993; 48:414–20.
65. Sandler DP. Recent studies in leukemia epidemiology. *Curr Opin Oncol* 1995; 7:12–8.
66. Wen W, Shu X, Potter J. Parental medication use and risk of childhood acute lymphoblastic leukemia. *Cancer* 2002; 95:1786–94.
67. Bethwaite P, Cook A, Kennedy J, Pearce N. Acute leukemia in electrical workers: a New Zealand case-control study. *Cancer Causes Control* 2001; 12:683–9.
68. Greaves M, Alexander F. An infectious etiology for common acute lymphoblastic leukemia in childhood? *Leukemia* 1993; 7:349–60.
69. Lombardi L, Newcomb E, Dalla-Favera R. Pathogenesis of Burkitt's lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected B lymphoblasts. *Cell* 1987; 49:161–70.
70. Timonen T. A hypothesis concerning deficiency of sunlight, cold temperature, and influenza epidemics associated with the onset of acute lymphoblastic leukemia in northern Finland. *Ann Hematol* 1999; 78:408–14.
71. Pedersen-Bjergaard J. Acute lymphoid leukemia with t(4; 11)(q21;q23) following chemotherapy with cytostatic agents targeting at DNA-topoisomerase II. *Leuk Res* 1992; 16:733–5.
72. Frankel S, Herzig G, Bloomfield C. Acute lymphoid leukemia in adults. In: Abeloff M, Armitage J, Lichter A, Niederhuber J, editors. *Clinical oncology*, 1st edition. New York: Churchill Livingstone 1995:1925–58.
73. Jaing T, Hsueh C, Chiu C. Cutaneous lymphocytic vasculitis as the presenting feature of acute lymphoblastic leukemia. *J Pediatr Hematol Oncol* 2002; 24:555–7.
74. Mayo G, Carter J, McKinnon S. Bilateral optic disk edema and blindness as initial presentation of acute lymphocytic leukemia. *Am J Ophthalmol* 2002; 134:141–2.

75. Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. *Hematol Oncol Clin North Am* 2001; 15:145–62.
76. Ye C, Echeverri C, Anderson J. T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor. *Hum Pathol* 2002; 33:770–3.
77. Attarbaschi A, Mann G, Dworzak M. Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: significance and therapy response. *Med Pediatr Oncol* 2002; 39: 558–65.
78. Fenaux P, Bourhuis J, Ribrag V. Burkitt's acute lymphocytic leukemia (L3 ALL) in adults. *Hematol Oncol Clin North Am* 2001; 15:37–50.
79. Figueroa M, Lughart S, Li Y. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. *Cancer cell* 2010; 17: 13-27.
80. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. *Leukemia* 1996; 14:877–95.
81. Bene M, Castoldi G, Knapp W. Proposals for the immunological classification of acute leukemias. *Leukemia* 1995; 9:1783–6.
82. Faderl S, Kantarjian H, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. *Blood* 1998; 91:3995–4019.
83. Groupe Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with the hematologic findings and outcome. A collaborative study of the Groupe Francais de Cytogenetique Hematologique. *Blood* 1996;87: 3135–42.
84. Patte C, Auperin A, Michon J, Behrendt H. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. *Blood* 2001; 97: 3370–79.
85. Laport G, Larson R. Treatment of adult acute lymphoblastic leukemia. *Semin Oncol* 1997; 24:70-82.
86. Balis F, Lester C, Chrousos G, Heideman R, Poplack D. Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. *J Clin Oncol* 1987;5:202-7.
87. Bostrom B, Gaynon P, Sather H. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL). *Proc Am Soc Clin Oncol* 1998; 17:527A.
88. Veerman A, Hahlen K, Kamps W. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. *J Clin Oncol* 1996; 14:911-8.

89. Copelan E, McGuire E. The biology and treatment of acute lymphoblastic leukemia in adults. *Blood* 1995; 85:1151-68.
90. Cuttner J, Mick R, Budman D. Phase III trial of brief intensive treatment of adult acute lymphoblastic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. *Leukemia* 1991; 5:425-31.
91. Fière D, Lepage E, Sebban C. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. *J Clin Oncol* 1993; 11:1990-2001.
92. Mahoney D, Shuster J, Nitschke R. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. *J Clin Oncol* 1998; 16:246-54.
93. Schorin M, Blattner S, Gelber R. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/ Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. *J Clin Oncol* 1994; 12:740-7.
94. Chessells J, Bailey C, Richards S. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. *Lancet* 1995; 345:143-8.
95. Reiter A, Schrappe M, Ludwig W-D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. *Blood* 1994; 84:3122-33.
96. Gyanon P, Steinherz P, Bleyer W. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. *J Clin Oncol* 1993; 11:2234-42.
97. Pui C-H, Crist W. Biology and treatment of acute lymphoblastic leukemia. *J Pediatr* 1994; 124:491-503.
98. Nachman J, Sather H, Cherlow J. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. *J Clin Oncol* 1998; 16:920-30.
99. Pui C-H, Mahmoud H, Rivera G. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. *Blood* 1998; 92:411- 5.
100. Appelbaum F. Allogeneic hematopoietic stem cell transplantation for acute leukemia. *Semin Oncol* 1997; 24:114-23.
101. Barrett A, Horowitz M, Pollock B. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. *N Engl J Med* 1994; 331:1253-8.

102. Uderzo C, Valsecchi M, Bacigalupo A. Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology Association. *J Clin Oncol* 1995; 13:352-8.
103. Diem T, Albert G, Frauman T, Colin I, Maurice E. Angiotensin receptors: distribution, signaling and function. *Clinical science* 2001; 100: 481- 92.
104. Johnston, Franz V. Renin-angiotensin system: a dual tissue and hormonal system for cardiovascular control. *J. Hypertens* 1992; 10: S13-26.
105. Vinson G, Ho M., Puddefoot, J. The distribution of angiotensin II type 1 receptors, and the tissue rennin-angiotensin systems. *Mol Med Today* 1995; 1: 35-9.
106. Urata, H., Nishimura, H., Ganten, D. Mechanisms of angiotensin II formation in humans. *Eur Heart J* 1995; 16: 79-85.
107. Urata H., Nishimura H., Ganten D., Arakawa K. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. *Blood Pressure* 1996; 2:22-8.
108. Dzau V. Cell biology and genetics of angiotensin in cardiovascular disease. *J. Hypertens* 1994; 12:S3-S10
109. Timmermans P. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. *Hypertens Res* 1999; 22: 147-53.
110. de Gasparo M, Husain A., Alexander W, Catt K., Chiu A, Drew M, et al Proposed update angiotensin receptor nomenclature. *Hypertension* 1995; 25: 924-7.
111. Timmermans P, Wong P, Chiu A. Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 1993; 45: 205-51.
112. Horiuchi M. Functional aspects of angiotensin type 2 receptor. *Adv Exp Med Biol* 1996; 396: 217-24.
113. Csikos T, Chung O, Unger T. Receptors and their classification : focus on angiotensin II and the AT1 receptor. *J. Human Hypertens* 1998; 12: 311-8.
114. Chiu A, McCall D, Nguyen T. Discrimination of angiotensin II receptor subtypes by dithiothreitol. *Eur J Pharmacol* 1989; 170: 117-8.
115. Guo D, Furuta H, Mizukoshi M, Inagami T. The genomic organization of human angiotensin II type 1 receptor. *Biochem. Biophys Res Commun* 1994; 200: 313-9.
116. Griendling K, Alexander R. The angiotensin (AT1) receptor. *Semin Nephrol* 1993; 13: 558-66.
117. Hunyady L, Balla T, Catt K. The ligand binding site of the angiotensin AT1 receptor. *Trends Pharmacol Sci* 1996; 17: 135-40.

118. Groblewski T, Maigret B, Nouet S, Larguier R, Lombard C, Bonnafous, J, Marie J. Amino acids of the third transmembrane domain of the AT1A angiotensin II receptor are involved in the differential recognition of peptide and nonpeptide ligands. *Biochem Biophys Res Commun* 1995; 209: 153-60.
119. Thomas W, Thekkumkara T, Baker K. Molecular mechanisms of angiotensin II (AT1A) receptor endocytosis. *Clin Exp Pharmacol Physiol* 1996; 3: S74-80.
120. Griendling K, Lassegue B, Alexander R. Angiotensin receptors and their therapeutic implications. *Ann Rev Pharmacol Toxicol* 1996; 36: 281-306.
121. Capponi A. Distribution and signal transduction of angiotensin II AT1 and AT2 receptors. *Blood Pressure* 1996; 2:41-6.
122. Pobiner B, Hewlett E, Garrison J. Role of Ni in coupling angiotensin receptors to inhibition of adenylate cyclase in hepatocytes. *J Biol Chem* 1985; 260: 16200-9
123. Apfeldorf W, Rasmussen H. Simultaneous determination of intracellular free calcium and aldosterone production in bovine adrenal zona glomerulosa. *Cell Calcium* 1988; 9: 71-80.
124. Schieffer B, Paxton W, Marrero M, Bernstein K. Importance of tyrosine phosphorylation in angiotensin II type 1 receptor signaling. *Hypertension* 1996; 27: 476-80
125. Marrero M, Schieffer B, Paxton W, Heerdt L, Berk B, Delafontaine P, et al. Direct stimulation of JAK/STAT pathway by the angiotensin II AT2 receptor. *Nature (London)* 1995; 375: 247-50.
126. Sadoshima J, Izumo S. Signal transduction pathways of angiotensin II-induced c-fos gene expression in cardiac myocytes in vitro. Roles of phospholipid derived second messengers. *Circ Res* 1993; 73: 424-38.
127. Song K., Allen A, Paxinos G, Mendelsohn F. Mapping of angiotensin II receptor subtype heterogeneity in rat brain. *J Comp Neurol* 1992; 316: 467-84.
128. Aldred G, Chai S, Song K, Zhuo J, MacGregor D, Mendelsohn F. Distribution of angiotensin II receptor subtypes in the rabbit brain. *Regul Pept* 1993; 44: 119-30.
129. Barnes J, Steward L, Barber P. Identification and characterisation of angiotensin II receptor subtypes in human brain. *Eur J Pharmacol* 1993; 230: 251-8.
130. MacGregor D, Murone C, Song K, Allen A, Paxinos G, Mendelsohn F. Angiotensin II receptor subtypes in the human central nervous system. *Brain Res* 1995; 675: 231-40.
131. Lenkei Z, Palkovits M, Corvol P, Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type-2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. *Front Neuroendocrinol* 1997; 18: 383-439.

132. Montiel M, Barker S, Vinson G, Jimenez E. Angiotensin II receptor isoforms in the rat adrenal gland: studies with the selective subtype antagonists DuP 753 and CGP42112A. *J Mol Endocrinol* 1993; 11: 69-75.
133. Zhuo, J, MacGregor D, Mendelsohn, F. Comparative distribution of angiotensin II receptor subtypes in mammalian adrenal glands. In *Adrenal Glands, Vascular System and Hypertension*. *J Endocrin* 1996; 53-68.
134. Allen A, Yamada H, Mendelsohn F. In vitro autoradiographic localization of binding to angiotensin receptors in the rat heart. *Int J Cardiol* 1990; 28: 25-33.
135. Saavedra J, Viswanathan M, Shigematsu. Localization of angiotensin AT2 receptors in the rat heart conduction system. *Eur J Pharmacol* 1993; 235: 301-3.
136. Zhuo J, Allen A, Alcorn D, Aldred G, MacGregor D, Mendelsohn F. The distribution of angiotensin II receptors. In *Hypertension: Pathophysiology, Diagnosis, and Management* 1995; 1739-62.
137. Zhuo J, Alcorn D, Harris P, McCausland J, Aldred G, Mendelsohn F. Angiotensin II receptor subtypes in the kidney: Distribution and function. *Nephrology* 1997; 1: 511-25.
138. Dinh D, Frauman A, Sourial M, Casley D, Johnston C, Fabiani M. Identification, distribution and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. *Endocrinology* 2001;142:1349-56.
139. Hughes A. Molecular and cellular mechanisms of action of angiotensin II (AT2) receptors in vascular smooth muscle. *J Human Hypertens* 1998; 12: 275-81.
140. Moravec C, Schluchter M, Paranandi L, Czarska B, Stewart R, Rosenkranz E, et al. Inotropic effects of angiotensin II on human cardiac muscle in vitro. *Circulation* 1990; 82: 1973-84.
141. Huckle W, Earp H. Regulation of cell proliferation and growth by angiotensin II. *Prog Growth Factor Res* 1994; 5: 177-94.
142. Rosendorff C. The rennin-angiotensin system and vascular hypertrophy. *J Am Coll Cardiol* 1996; 28: 803-12.
143. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? *J Hypertens* 1991; 9: 3-15.
144. Baker K, Booz G, Dostal D. Cardiac actions of angiotensin II : Role of an intracardiac rennin-angiotensin system. *Ann Rev Physiol* 1992; 54: 227-41.
145. Paradis P, Dali-Youcef N, Paradis F, Thibault G, Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. *Proc Natl Acad Sci* 2000; 97: 931-6.
146. Saxena P. Interaction between the rennin-angiotensin-aldosterone and sympathetic nervous systems. *J Cardiovasc Pharmacol* 1992; 19: S80-8.

147. Giacchetti G, Opocher G, Sarzani R, Rappelli A, Mantero F. Angiotensin II and the adrenal. *Clin Exp Pharmacol Physiol* 1996; 3:S119-24.
148. Aguilera G, Kiss A. Regulation of the hypothalamic pituitary-adrenal axis and vasopressin secretion. Role of angiotensin II. *Adv Exp Med Biol* 1996; 396: 105-12.
149. Bell P, Peti-Peterdi J. Angiotensin II stimulates macula densa basolateral sodium/hydrogen exchange via type 1 angiotensin II receptors. *J Am Soc Nephrol* 1999; 10: S225-9.
150. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? *Trends in Endocrinology and Metabolism* 2005; 16: 293- 99.
151. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. *Mol Cancer Ther* 2003; 2:1139-47.
152. Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J. Blockage of angiotensin II type 1 receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. *Br. J. Cancr* 2005; 92:1247-52.
153. Lindholm LH, Anderson H, Ekblom T, Hansson L, Lanke J, Dahlöf B, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. *Lancet* 2001; 358: 539- 44.
154. Greco S, Muscella A, Elia MG, Romano S, Storelli C, Marsigliante S. Mitogenic signalling by B2 bradykinin receptor in epithelial breast cells. *J Cell Physiol* 2004; 201:84-96.
155. Elbaz N, Bedecs K, Masson M, Sutren M, Strosberg AD, Nahmias C. Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor. *Mol Endocrinol* 2000; 14: 795-804.
156. Shibasaki Y, Matsubara H, Nozawa Y, Mori Y, Masaki H, Kosaki A, et al. Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase. *Hypertension* 2001; 38: 367-72.
157. Wu C, Sun M, Liu L, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. *Gene* 2003; 300:1-12.
158. Knowle D, Ahmed S, Pulakat L. Identification of an interaction between the angiotensin II receptor sub-type AT2 and the ErbB3 receptor, a member of the epidermal growth factor receptor family. *Regul Pept* 2000; 87: 73-82.

159. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. *J. Biol. Chem* 2004;279:28989-97.
160. Wruck CJ, Funke-Kaiser H, Pufe T, Kusserow H, Menk M, Schecke JH, et al. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. *Arterioscler Thromb Vase Biol* 2005; 25:57-64.
161. Seibold S, Rudroff C, Weber M, Galle J, Wanner C, Marx M. Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. *FASEB J* 2003; 17:1180-382.
162. Watanabe T, Barker T, Berk B. Angiotensin II and the endothelium: diverse signals and effects. *Hypertension* 2005; 45:163-9.
163. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. *Hypertens Res* 2004; 27:101-8.
164. Otani A, Takagi H, Oh H, Koyama S, Honda Y. Angiotensin II induces expression of the Tie-2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. *Diabetes* 2001; 50: 867-75.
165. Fujiyama S, Matsubara H, Nozawa Y, Maruyama K, Mori Y, Tsutsumi Y. (2001) Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding - epidermal growth factor (EGF)-mediated EGF receptor transactivation. *Circ Res* 2001; 88: 22-9.
166. Ohashi H, Takagi H, Oh H, Suzuma K, Suzuma I, Miyamoto N, et al. Phosphatidylinositol 3-kinase/Akt regulates angiotensin II-induced inhibition of apoptosis in microvascular endothelial cells by governing survivin expression and suppression of caspase-3 activity. *Circ Res* 2004; 94: 785-93.
167. Benndorf R, Böger R, Ergün S, Steenpass A, Wieland T. Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells. *Circ Res* 2003; 93:438-47.
168. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. *Int J Biochem Cell Biol* 2003; 35:881-900.
169. Wu L, Iwai M, Li Z, Shiuchi T, Min LJ, Cui TX, et al. (2004) Regulation of inhibitory protein-kappa B and monocyte chemoattractant protein-1 by angiotensin II type 2 receptor- activated Src homology protein tyrosine phosphatase-1 in fetal vascular smooth muscle cells. *Mol Endocrinol* 2004; 18: 666-78.
170. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh W, Law R. Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. *Hypertension* 2001; 37: 587-93.

171. El Bekay R, Alvarez M, Monteseirín J, Alba G, Chacón P, Vega A, et al. Oxidative stress is a critical mediator of the angiotensin II signal in human neutrophils: involvement of mitogen- activated protein kinase, calcineurin, and the transcription factor NF-kB. *Blood* 2003; 102:662-71.
172. Pueyo M, Gonzalez W, Nicoletti A, Savoie F, Arnal J, Michel JB. Angiotensin II stimulates endothelial vascular- cell adhesion molecule-1 via nuclear factor-kappa B activation induced by intracellular oxidative stress. *Arterioscler Thromb Vase Biol* 2000; 20: 615-51.
173. Brasier A, Recinos A, Eledrisi M. Vascular inflammation and the renin- angiotensin system. *Arterioscler Thromb Vase Biol* 2002; 22: 1257-66.
174. Lindberg H, Nielsen D, Jensen B, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? *Acta Oncol* 2004; 43:142 – 52.
175. Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. *J Pathol* 2004;202:330- 5
176. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65 – 79 years. *Cancer* 2003; 98:1504–13.
177. Freitas-Silva M, Pereira D, Coelho C, Bicho M, Lopes C, Medeiros R. Angiotensin I-converting enzyme gene, insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. *Cancer Genet Cytogenet* 2004; 155: 42-6.
178. Neo J. Effect of ACE inhibitors and angiotensin II-receptor antagonists in a mouse model of colorectal cancer liver metastases. *J Gastroenterol Hepatol* 2007; 22: 577 – 84.
179. Dacie J, and Lewis S. Basic hematological techniques. In: *Practical hematology 13th (ed) Ediangburgh, London, Melbourne, New York. Churchill Living stone* 2009; 3: 19- 46.
180. Leng S., McElhaney J., Walston J., Xie D., Fedarko N., Kuchel G. Elisa and Multiplex Technologies for Cytokine Measurement in Inflammation and Aging Research. *J Gerontol a Biol Sci Med Sci* 2008; 63 (8): 879–84.
181. Mona A. Yehia, Nadia A. Sadek. Mast cell chymase: a simple method for identification of acute myeloblastic leukemia. *J Med Res Inst* 1998; 19(suppl 1): 145- 53.
182. Hunyady L. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. *Mol. Endocrinol* 2006; 20: 953–70.
183. Angela M, Gonzalez-Zulocta L, Vasquez AR, Fakhredin A, Tabatabali S. Angiotensin converting enzyme gene insertion / deletion polymorphism and breast cancer risk. *Cancer Epidemiol Biomarkers Prev* 2005; 14(9): 2143-6.

184. Hilgers K, Matthias R, Langenfeld W. 1166 A/C polymorphism of the angiotensin II type 1 receptor gene the response to short-term infusion of angiotensin II. *Circulation* 1999; 100: 1394- 9.
185. Koh W, yuan I, Sun C. Angiotensin I converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese woman in Singapore. *Cancer Res* 2003; 63: 573- 8.
186. Greco S, Muscella A, Elia M. Angiotensin II activates extracellular signal regulated kinases via protein kinase C and epidermal growth factor in breast cancer cells. *J Cell Physiol* 2003; 196: 370- 7.
187. Rigat B, Hubert C, Athene-Gelast F. An insertion / deletion polymorphism in the angiotensin I converting enzyme gene accounting for half the variance of serum enzyme level. *J Clin Invest* 1990; 86: 1343- 6.
188. Jokubaitis V, Sinka L, Driessen R, Whitty G, Haylock D, Bertonecello I, et al. Angiotensin converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. *Blood* 2008; 111: 4055- 63.
189. Aksu S, Beyazit Y, Ibrahim C. Over expression of angiotensin – converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. *Leuk, Lymphoma* 2006; 47 (5): 891-6.
190. Atrawn W, Richmond R, ANN T, Gallagher P. Renin-angiotensin system expression in rat bone marrow hematopoietic and stromal cells. *B J H* 2004; 126: 120-6.
191. Abali H, Haznedoroglu I, Goker H, Celik T. Circulating and local bone marrow rennin-angiotensin system in leukemic hematopoiesis: preliminary evidences. *Hematology* 2002; 7: 75- 82.
192. Casares TG, De la Zeglesias, Perera M. Renin expression in hematological malignancies and its role in the regulation of the hematopoiesis. *Leuk Lymphoma* 2002; 43: 2377-81.
193. Pinto R, Wang K, Khoury H. Abberant expression of angiotensin in acute myeloid leukemia. *Blood* 2004; 102: 2124 A.
194. Silvestre J, Bergaya S, Tamarat R. Proangiogenic effect of angiotensin- converting enzyme inhibition is mediated by the Bradykinin B2 receptor pathway. *Circ Res* 2001; 89: 678- 83.
195. Heringer-Walther S, Eckert K, Schumacher S. Angiotensin (1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. *Haematologica* 2009; 94(6): 857- 60.
196. Takeda H, Katagata Y, Hozumi Y, Kondo S. Effects of angiotensin II receptor signaling during skin wound healing. *Am J Pathol* 2004; 165: 1653- 62.

197. Ellefson D, Dizerega G, Espinoza T. Synergistic effects of co-administration of angiotensin 1-7 and Neupogen on hematopoietic recovery in mice. *Cancer Chem Pharmacol* 2004; 53: 15- 24.
198. Roders K, Xiong S, Dizerega G. Effect of angiotensin II and angiotensin (1-7) on hematopoietic recovery after intravenous chemotherapy. *Cancer Chemother Pharmacol* 2003; 51: 97- 106.
199. Shen X, Xiao H, Li P, Billet S, Lin CX, Fuchs S, et al. Tissue specific expression of angiotensin converting enzyme: a new way to study an old friend. *Int Immunopharmacol* 2008;8:171-6.
200. Egami K, Murohara T, Shimada T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. *J Clin Invest* 2003; 112(1): 67- 75.
201. Fujita M, Hayashi F, Yamashina S, Itoman M. Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis and metastasis. *Biochem Biophys Res Commun* 2002; 294: 441- 7.
202. Miyajima A. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibition tumor angiogenesis. *Cancer Res* 2002; 62: 4176-9.
203. Wulf G, Streubel J, Strutz F. Paraneoplastic hypokalemia in acute myeloid leukemia: a case of rennin activity in AML blast cells. *Ann Hematol* 1996; 73: 139-44.
204. Awais M., Jeffery E, Mohamed A. Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML). *J Clin Oncol* 2012; 30.

Declaration

I declare that no part of the work referred to in this thesis had been submitted in support of an application for another degree or qualification of this or any other University or other Institution of learning.

Name:

Signature



جامعة الإسكندرية
معهد البحوث الطبية
قسم الكيمياء الطبية التطبيقية

القيمة التكهنية للمستقبل رقم ١ للانجيوتنسين ٢ الذائب و انزيم تحويل الانجيوتنسين الذائب (سي دي ١٤٣) في مرضي سرطان الدم الحاد

رسالة مقدمة

لقسم الكيمياء الطبية التطبيقية - معهد البحوث الطبية - جامعة الإسكندرية
ضمن متطلبات درجة

دكتوراه الفلسفة

فى

الكيمياء الطبية التطبيقية

من

هبة خفاجي أحمد الكاشف

ماجستير الكيمياء الطبية التطبيقية، ٢٠٠٦
معهد البحوث الطبية، جامعة الإسكندرية

بكالوريوس علوم - كيمياء حيوية، ١٩٩٨
كلية العلوم - جامعة الإسكندرية

معهد البحوث الطبية
جامعة الإسكندرية

٢٠١٤



جامعة الإسكندرية
معهد البحوث الطبية
قسم الكيمياء الطبية التطبيقية

القيمة التكهنية للمستقبل رقم ١ للانجيوتنسين ٢ الذائب و انزيم تحويل
الانجيوتنسين الذائب (سي دي ١٤٣) في مرضي سرطان الدم الحاد

رسالة مقدمة من

هبة خفاجي أحمد الكاشف

للحصول على درجة

دكتوراه الفلسفة

في

الكيمياء الطبية التطبيقية

التوقيع

.....

.....

.....

.....

لجنة المناقشة والحكم على الرسالة

أ.د/ سامية عبد المنعم عبيد

أستاذ الكيمياء الطبية التطبيقية

قسم الكيمياء الطبية التطبيقية

معهد البحوث الطبية

جامعة الإسكندرية

أ.د/ نادية علي صادق

أستاذ أمراض الدم

قسم أمراض الدم

معهد البحوث الطبية

جامعة الإسكندرية

أ.د/ عبد الله فوده

أستاذ الكيمياء الحيوية

قسم الكيمياء الحيوية

كلية الطب

جامعة طنطا

أ.د/ هالة قاسم سلطان

أستاذ أمراض الدم

قسم أمراض الدم

معهد البحوث الطبية

جامعة الإسكندرية

التاريخ / /

لجنة الإشراف

موافقون

.....
الأستاذة الدكتورة/ سامية عبد المنعم عبيد

أستاذ الكيمياء الطبية التطبيقية
قسم الكيمياء الطبية التطبيقية
معهد البحوث الطبية
جامعة الإسكندرية

.....
الأستاذة الدكتورة/ نادية علي صادق

أستاذ أمراض الدم و مدير بنك الدم
قسم أمراض الدم
معهد البحوث الطبية
جامعة الإسكندرية

.....
الأستاذة الدكتورة/ نادية السيد زكي

أستاذ الامراض الباطنة
وحدة أمراض الدم
كلية الطب
جامعة الإسكندرية

إقرار

أقر أنه لا يوجد أى جزء من هذا العمل قد سبق تقديمه لنيل درجة أخرى فى هذا المعهد أو أى جامعة أو مؤسسة تعليمية أخرى.

اسم الطالب:

توقيعه: